Sting agonists, compositions, and uses thereof
By developing a novel non-cyclic dinucleotide STING agonist combined with a nanocarrier, the problems of poor permeability and weak binding affinity of existing STING agonists were solved, achieving oral administration and significant anti-tumor effects, thus enhancing the pharmacokinetics and therapeutic efficacy of cancer treatment.
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- THE RGT UNIV OF MICHIGAN
- Filing Date
- 2024-10-30
- Publication Date
- 2026-07-17
AI Technical Summary
Existing STING agonists suffer from poor permeability, low stability, and weak binding affinity in clinical applications, which limits their effectiveness in cancer treatment.
A novel noncyclic dinucleotide (STING) agonist has been developed. When administered orally or intravenously, it is combined with nanocarriers such as albumin nanoparticles and liposomes to enhance pharmacokinetic properties. When used in combination with immunomodulators, it activates the STING signaling pathway and induces the expression of interferon and inflammatory factors.
It achieves favorable pharmacokinetic properties and significant antitumor efficacy of non-CDN STING agonists, enhancing the therapeutic effect on cancer, especially showing significant in vivo antitumor activity when used in combination with immune checkpoint inhibitors.
Smart Images
Figure FT_1 
Figure FT_2 
Figure FT_3